New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - amoxicillin trihydrate 287.5mg equivalent to amoxycillin 250 mg;   - capsule - 250 mg - active: amoxicillin trihydrate 287.5mg equivalent to amoxycillin 250 mg   excipient: gelatin magnesium stearate microcrystalline cellulose purified talc sodium starch glycolate - amoxicillin should be used in accordance with local antibiotic-prescribing information guidelines and local susceptibility data. amoxicillin may be useful in instituting therapy prior to bacteriology; however bacteriological studies to determine the causative organisms and their sensitivity to amoxicillin should be performed. susceptibility to amoxicillin will vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary. treatment of infection: amoxicillin is indicated in the treatment of infections due to susceptible organisms. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli. respiratory (acute and chronic): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase-producing; e.coli. genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p. mirabilis and s. faecalis. gonorrhoea: n. gonorrhoeae (non-penicillinase producing). prophylaxis for endocarditis: amoxicillin may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis, such as those with a prosthetic heart valve or those who have previously had endocarditis.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - amoxicillin trihydrate 287.5mg equivalent to amoxycillin 250 mg - capsule - 250 mg - active: amoxicillin trihydrate 287.5mg equivalent to amoxycillin 250 mg excipient: gelatin magnesium stearate sodium laurilsulfate

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 286.96 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 573.921 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide black; microcrystalline cellulose; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 57.8 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: saccharin sodium; colloidal anhydrous silica; xanthan gum; sodium citrate dihydrate; sunset yellow fcf; sorbitol; flavour - indications: it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see section 5.1 pharmacodynamic properties - microbiology), p. mira

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 28.9 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sunset yellow fcf; colloidal anhydrous silica; xanthan gum; saccharin sodium; sodium citrate dihydrate; sorbitol; flavour - indications: it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see section 5.1 pharmacodynamic properties - microbiology), p. mira

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amoxicillin trihydrate, quantity: 1004.5 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 148.87 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: ethylcellulose; purified talc; triethyl citrate; polysorbate 80; crospovidone; croscarmellose sodium; magnesium stearate; hyprolose; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide - amoxycillin and clavulanic acid tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infection

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 28.77 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthe

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 57.4 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; sodium citrate; purified talc; aspartame; sodium benzoate; citric acid; guar gum; flavour - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. amoxycillin alone or in combination with another antibiotic, may be used in an emergency where the causative organism has not been identified. respiratory tract infections (acute and chronic) including acute otitis media (aom): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). skin and skin structure infections: staphlococcus, nonpenicillinase producing; streptococcus, e. coli (see microbiology). prophlaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthe

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -